Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 615

1.

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.

Burmester GR, Landewé R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP.

Ann Rheum Dis. 2016 Jun 23. pii: annrheumdis-2016-209322. doi: 10.1136/annrheumdis-2016-209322. [Epub ahead of print]

2.

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.

Ann Rheum Dis. 2016 May 10. pii: annrheumdis-2015-209057. doi: 10.1136/annrheumdis-2015-209057. [Epub ahead of print]

3.

Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.

Heldmann F, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):184-90. Epub 2016 Mar 25.

PMID:
27049733
4.

Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.

Martínez G, Gómez JA, Bang H, Martínez-Gamboa L, Roggenbuck D, Burmester GR, Torres B, Prada D, Feist E.

Rheumatol Int. 2016 Jun;36(6):781-91. doi: 10.1007/s00296-016-3472-9. Epub 2016 Apr 2.

5.

Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.

Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Peichl P, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M.

Clin Exp Rheumatol. 2016 May-Jun;34(3):489-99. Epub 2016 Mar 10.

PMID:
26966919
6.

The changing landscape of biosimilars in rheumatology.

Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR.

Ann Rheum Dis. 2016 Jun;75(6):974-82. doi: 10.1136/annrheumdis-2016-209166. Epub 2016 Mar 8. Review.

7.

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.

Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Elbez Y, Le Bars M.

RMD Open. 2016 Feb 15;2(1):e000228. doi: 10.1136/rmdopen-2015-000228. eCollection 2016.

8.

Increased Periodontal Attachment Loss in Systemic Sclerosis Patients.

Pischon N, Hoedke D, Kurth S, Lee P, Dommisch H, Steinbrecher A, Pischon T, Burmester GR, Buttgereit F, Detert J, Riemekasten G.

J Periodontol. 2016 Feb 28:1-12. [Epub ahead of print]

PMID:
26923473
9.

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.

Peterfy C, Burmester GR, Bykerk VP, Combe BG, DiCarlo JC, Furst DE, Huizinga TW, Wong DA, Conaghan PG, Emery P.

Ann Rheum Dis. 2016 Feb 10. pii: annrheumdis-2015-208258. doi: 10.1136/annrheumdis-2015-208258. [Epub ahead of print]

10.

Disentangling the effects of tocilizumab on neutrophil survival and function.

Gaber T, Hahne M, Strehl C, Hoff P, Dörffel Y, Feist E, Burmester GR, Buttgereit F.

Immunol Res. 2016 Jun;64(3):665-76. doi: 10.1007/s12026-015-8770-x.

PMID:
26721805
11.

Rheumatische und muskuloskelettale Erkrankungen--eine wissenschaftliche und klinische Herausforderung.

Burmester GR.

Drug Res (Stuttg). 2015 Nov;65 Suppl 1:S2. doi: 10.1055/s-0035-1558059. Epub 2015 Nov 4. German. No abstract available.

PMID:
26536183
Free Article
12.

Therapie muskuloskelettaler Erkrankungen--Stand und Perspektiven.

Burmester GR, Endres S.

Drug Res (Stuttg). 2015 Nov;65 Suppl 1:S1. doi: 10.1055/s-0035-1558110. Epub 2015 Nov 4. German. No abstract available.

PMID:
26536176
Free Article
13.

Biologicals in rheumatoid arthritis: current and future.

Avci AB, Feist E, Burmester GR.

RMD Open. 2015 Aug 5;1(1):e000127. doi: 10.1136/rmdopen-2015-000127. eCollection 2015. Review.

14.

Improvements in Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study.

Emery P, Bingham C, Burmester GR, Bykerk VP, Furst D, Mariette X, Purcaru O, VanLunen B, Weinblatt M.

Value Health. 2015 Nov;18(7):A710. doi: 10.1016/j.jval.2015.09.2671. Epub 2015 Oct 20. No abstract available.

PMID:
26533977
15.

ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.

Iking-Konert C, von Hinüber U, Richter C, Schwenke H, Gürtler I, Kästner P, Klapperich B, Peters MA, Burmester GR.

Rheumatology (Oxford). 2016 Apr;55(4):624-35. doi: 10.1093/rheumatology/kev372. Epub 2015 Oct 29.

16.

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.

Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N.

Ann Rheum Dis. 2016 Jun;75(6):1081-91. doi: 10.1136/annrheumdis-2015-207628. Epub 2015 Oct 28.

17.

Introducing RMD Open.

Cutolo M, Burmester GR, Kvien TK.

RMD Open. 2015 Feb 18;1(1):e000031. doi: 10.1136/rmdopen-2014-000031. eCollection 2015. No abstract available.

18.

Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?

Buttgereit F, Burmester GR, Bijlsma JW.

RMD Open. 2015 Feb 18;1(1):e000027. doi: 10.1136/rmdopen-2014-000027. eCollection 2015.

19.

[Biosimilars].

Burmester GR, Müller-Ladner U.

Z Rheumatol. 2015 Oct;74(8):670-1. doi: 10.1007/s00393-014-1490-0. German. No abstract available.

PMID:
26450433
20.

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.

von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, Enghard P, Sawitzki B, Hiepe F, Radbruch A, Burmester GR, Riemekasten G, Humrich JY.

Ann Rheum Dis. 2016 Jul;75(7):1407-15. doi: 10.1136/annrheumdis-2015-207776. Epub 2015 Aug 31.

PMID:
26324847
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk